DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today the launch of the Sharesource Analytics 1.0 premium module, the next generation of digital health for home-based peritoneal dialysis (PD) patients. Sharesource Analytics 1.0 is a clinical management resource within the Sharesource remote patient management platform that provides healthcare professionals with a comprehensive dashboard containing simplified trend data from their home dialysis patients’ treatments. Baxter plans on launching Sharesource Analytics 1.0 globally, initiating in the United States, on a rolling basis over the next year and making it available by subscription.
Sharesource Analytics 1.0 delivers intuitive and clinically meaningful data that may be used to identify potentially slow-building issues over the patient’s last 180 days of therapy. This data provides clarity to healthcare professionals around their patients’ adherence, catheter function and therapy fatigue – three issues often associated with therapy dropout.1 It also provides healthcare professionals with evidence-based clinical guidance to aid in making informed decisions to resolve the potential complications their home patients may be experiencing.
“Sharesource remote patient management platform has played a significant role through the COVID-19 pandemic in allowing patients with kidney failure—who often have immune dysfunction—to do their dialysis at home, where they can remain safer by socially distancing,” said Peter Rutherford, M.D., senior medical director, Baxter Renal Care business. “With the launch of Sharesource Analytics 1.0, Baxter is again pioneering the next generation of digital health for nephrology that is designed to further empower remote clinical management of home dialysis patients.”
About Sharesource Remote Patient Management
Sharesource Analytics 1.0 is built on Baxter’s pioneering digital health platform, Sharesource remote patient management. Sharesource remote patient management allows healthcare professionals to monitor their patients’ home dialysis treatments, and then remotely adjust therapy without the need for patients to make unplanned visits to the clinic as a general matter. Sharesource is the most widely used home dialysis digital health platform, used to care for 38% of all patients on automated PD globally, available in more than 70 countries, and it has managed more than 25 million treatments to date.
Supporting the broad global adoption of Sharesource is evidence that the remote patient management digital health platform can assist healthcare providers with early detection and intervention of catheter issues,2,3,4,5 peritonitis,6 and adherence-related complications,7,8,9 which can lead to reduced hospitalizations.10
About Peritoneal Dialysis
People living with end-stage renal disease require dialysis treatment or a kidney transplant to stay alive. PD therapy is typically managed by patients in their home, at a time of day that is convenient for them. It works by cleaning the blood of toxins and removing extra fluid through the body’s peritoneal cavity. Studies show patients and physicians often prefer home dialysis.11 PD patients experience improved early survival, and higher satisfaction rates and quality-of-life measures.12, 13, 14
Every day, millions of patients and caregivers rely on Baxter's leading portfolio of critical care, nutrition, renal, hospital and surgical products. For 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.
This release includes forward-looking statements concerning Sharesource remote patient management and Sharesource Analytics, including potential benefits associated with their use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.
Baxter and Sharesource are registered trademarks of Baxter International Inc.
1 Mujais S, Story K. Peritoneal dialysis in the US: evaluation of outcomes in contemporary cohorts. Kidney Int Suppl. 2006 Nov;(103):S21-6.
2 Jiménez S & Condia J. Abstract presented at 17th ISPD congress. Vancouver (Canada). 2018. [P-337]
3 Garcia I, et al. Abstract presented at 13th Euro-PD congress. Dublin (Ireland). 2017. [P-63]
4 Jotterand Drepper V, et al. Abstract presented at ASN Kidney Week congress. Chicago (US). 2016. [SA-PO023]
5 Rojas-Diaz M, et al. Abstract presented at ASN Kidney Week congress. New Orleans (US). 2017. [PUB344]
6 Gomez R, et al. Abstract presented at 13th Euro-PD congress. Dublin (Ireland). 2017. [P-222]
7 Jiménez S & Condia J. Abstract presented at 17th ISPD congress. Vancouver (Canada). 2018. [P-229]
8 Firanek C, et al. Abstract presented at 54th ERA-EDTA congress. Madrid (Spain). 2017. [MP557]
9 Jotterand Drepper V, et al. Perit Dial Int. 2018; 38:76–78; 10. Rojas-Diaz M & Ramos A. Abstract presented at ASN Kidney Week congress. New Orleans (US). 2017. [TH-PO859]
10 Rivera A, et al. Abstract presented at ASN Kidney Week congress. San Diego (US). 2018. [FR-PO683]
11 Rivara MB, Mehrotra R. The Changing Landscape of Home Dialysis in the United States. Current Opinion in Nephrology and Hypertension.2014; 23(6):586-591.doi:10.1097/MNH0000000000000066; Mehrotra R, Chiu YW, Kalantar-Zadeh K, Bargman J, Vonesh E. Similar Outcomes with Hemodialysis and Peritoneal Dialysis in Patients with End-Stage Renal Disease. Archives of Internal Medicine. 2011; 171(2): 110-118. Doi:10.1001/archinternmed.2010.352; Ledebo I, Ronco C. The best dialysis therapy? Results from an international survey among nephrology professionals. Nephrology Dialysis Transplantation.2008;6:403-408.doi:10.1093/ndtplus/sfn148; Schiller B, Neitzer A, Doss S. Perceptions about renal replacement therapy among nephrology professionals. Nephrology News & Issues. September 2010; 36-44; Ghaffarri A, Kalantar-Zadeh K, Lee J, Maddux F, Moran J, Nissenson A. PD First: Peritoneal Dialysis as the Default Transition to Dialysis Therapy. Seminars in Dialysis. 2013; 26(6): 706-713. doi: 10.1111/sdi.12125
12 Rubin HR et al. Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis. JAMA. 2004 Feb 11;291(6):697-703.
13 Juergensen, et al. Hemodialysis and peritoneal dialysis: patients’ assessment of their satisfaction with therapy and the impact of the therapy on their lives. Clin J Am Soc Nephrol. 2006; 1(6): 1191-1196.
14 Zazzeroni L HR et al. Comparison of quality of life in patients undergoing hemodialysis and peritoneal dialysis: a systematic review and meta-analysis. Kidney Blood Press Res. 2017;42(4):717-727. USRDS ADR 2018: Vol 2 ESRD, Chap 5; Fig 5.1.